Shawn Li

Dr. Shawn Li is currently a principal scientist and scientific supervisor in the Pharmaceutical Analysis & Digital Technologies, Mass Spectrometry group at Merck & Co. Inc. His research focused on mass spectrometry-based biologics and vaccine characterization for CMC development and regulatory submission. Prior to join Merck in 2018, Dr Li worked as a research scientist at Eli Lilly on protein characterization. Before his industry career, Dr Li was a director of the mass spectrometry facility at the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania. Dr. Li received a Ph.D. in proteomics at the Hunan Normal University in China and completed his post-doctoral training in clinical pharmacology and bioanalysis at the University of Pennsylvania. Dr. Li has authored over 50 peer-reviewed articles and book chapters, and has filed 4 industry patents.